Raymond James Financial Services Advisors Inc. Has $109.38 Million Stake in Edwards Lifesciences Co. (NYSE:EW)

Raymond James Financial Services Advisors Inc. boosted its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 4.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,144,581 shares of the medical research company's stock after acquiring an additional 46,217 shares during the period. Raymond James Financial Services Advisors Inc. owned 0.19% of Edwards Lifesciences worth $109,376,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Nordea Investment Management AB grew its stake in Edwards Lifesciences by 1,224.1% during the fourth quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company's stock worth $123,261,000 after buying an additional 1,488,791 shares during the last quarter. Telos Capital Management Inc. raised its holdings in Edwards Lifesciences by 158.2% in the fourth quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company's stock worth $6,970,000 after purchasing an additional 56,000 shares during the period. Arlington Trust Co LLC raised its holdings in Edwards Lifesciences by 5,092.4% in the fourth quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company's stock worth $938,000 after purchasing an additional 12,069 shares during the period. Versor Investments LP raised its holdings in Edwards Lifesciences by 83.3% in the third quarter. Versor Investments LP now owns 4,496 shares of the medical research company's stock worth $311,000 after purchasing an additional 2,043 shares during the period. Finally, HealthInvest Partners AB bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $1,587,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on EW. Royal Bank of Canada increased their price objective on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an "outperform" rating in a research report on Monday, April 15th. Evercore ISI lowered their price objective on shares of Edwards Lifesciences from $92.00 to $89.00 and set an "in-line" rating for the company in a research report on Friday, April 26th. Piper Sandler increased their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a "neutral" rating in a research report on Friday, April 26th. Bank of America raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating in a research report on Thursday, March 7th. Finally, Wells Fargo & Company raised their target price on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an "overweight" rating in a research report on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $92.71.

Edwards Lifesciences Stock Performance

Shares of EW traded down $0.44 during trading hours on Wednesday, hitting $84.23. The company's stock had a trading volume of 2,203,078 shares, compared to its average volume of 3,811,529. The company has a market cap of $50.70 billion, a price-to-earnings ratio of 36.31, a PEG ratio of 3.62 and a beta of 1.05. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The business has a 50 day simple moving average of $90.18 and a two-hundred day simple moving average of $79.19. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. On average, equities analysts expect that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Edwards Lifesciences news, Director Heisz Leslie Stone sold 7,056 shares of the business's stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $86.45, for a total transaction of $609,991.20. Following the transaction, the director now directly owns 26,980 shares of the company's stock, valued at approximately $2,332,421. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. Insiders sold a total of 215,654 shares of company stock worth $19,000,928 over the last three months. 1.27% of the stock is owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.